Építés alatt – nem éles oldal
Belépés

NCT04885257Befejeződött1/2. fázis

Methylphenidate for Ptsd and Stroke Veterans

A Randomized Placebo-controlled Trial of Methylphenidate in Veterans With a Diagnosis of Post Traumatic Stress Disorder and Recent Cerebral Stroke

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. jún. 22.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

Veterans with post-traumatic stress disorder (PTSD) have an increased risk of developing ischemic stroke. Veterans enduring PTSD face difficulties in managing their PTSD severity after suffering from a stroke. Currently, clinical trials in PTSD exclude patients with stroke and patients with significant premorbid psychological conditions like PTSD are usually excluded from stroke clinical trials. Methylphenidate (MPH) is a central nervous system stimulant that can improve PTSD symptoms: avoidance behaviors, social withdrawal, hyperarousal, and working memory. MPH can also improve post-stroke outcomes: mood, activities of daily living, and motor functioning. In clinical trials for PTSD or stroke, MPH has been shown to be well-tolerated with minimal adverse events. The high prevalence of PTSD in Veterans with stroke provides strong justification for development of interventions that effectively and simultaneously target both conditions. The overarching goal of our proposal is to understand how MPH improves PTSD severity in Veterans with comorbid stroke.

Állapot (regiszter)
Befejeződött
Fázis (regiszter)
1/2. fázis
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
20 (tényleges)
Első benyújtás
2021. máj. 3.
Kezdés
2022. jan. 14.
Elsődleges befejezés
2025. máj. 5.
Fő szponzor
VA Office of Research and Development
NCT-szám
NCT04885257

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó · 1/2. fázis
  • Bevont résztvevők: 20
  • 2022. jan. 14. és az elsődleges befejezés (2025. máj. 5.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Increased risk of suicide that necessitates inpatient treatment or warrants additional therapy excluded by the protocol; and/or intensity of suicidal ideation (Type 4 or Type 5) or any suicidal behavior in the past 3 months on Columbia Suicide Severity Rating Scale (C-SSRS)
  • Use of any investigational drug, MPH formulation, antipsychotics, mood stabilizers, monoamine oxidase inhibitors, stimulants or any medication known to be a potent (strong) cytochrome P450 subtype 3A4 inhibitor within 2 weeks of baseline
  • Treatment with evidence-based trauma-focused therapy for PTSD within two weeks of baseline (if participant is receiving therapy, he/she must complete treatment prior to entering study)
    • Supportive psychotherapy in process at time of Screening may be continued during the study.
  • Litigating for compensation for a psychiatric disorder. Veterans who are in the process of applying for or receiving VA service-connected disability are eligible

Más betegség

  • Moderate to severe cognitive impairment (Montreal Cognitive Assessment score <16/30)
  • Poor pre-stroke baseline function of a modified Rankin score >2
  • Current diagnosis of DSM-5-defined bipolar disorder I, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, or major depressive disorder with psychotic features (MINI)
  • Diagnosis of moderate or severe substance use disorder (except for caffeine and nicotine) during the preceding 3 months
    • Patients who utilize alcohol or cannabis but do not meet criteria for moderate or severe disorder are permitted at the discretion of the investigator
    • Participants must agree to abstain from illicit drugs during the study
  • History of moderate or severe TBI as defined by the Ohio State University TBI Identification Method
    • Based on investigator's clinical judgment, history of mild TBI is not excluded
  • Severe allergic reaction, bronchospasm, or hypersensitivity to any MPH formulation.
  • Current enrollment in another intervention trial for PTSD or stroke
  • Persons imprisoned, diagnosed with terminal illness, or require surrogate for consent

Laborértékek

  • Any clinically significant, uncontrolled, or medical/surgical condition or laboratory abnormality that would contraindicate use of MPH (see Human Subjects section)

Egyéb

  • Presence of any standard MRI contraindications

Kiket keres a vizsgálat

  • Male or female Veteran of US military; signed informed consent
  • Criterion A Index Trauma(s) resulting in PTSD occurred during adulthood prior to stroke
  • CAPS-5 past week total score =23 at baseline visit
  • Willing to refrain from antipsychotics, mood stabilizers, stimulants, and any formulation of MPH
  • First-ever symptomatic ischemic stroke radiologically verified, occurring within past 1-12 months
  • Females of child-bearing potential (i.e. not postmenopausal or surgically sterile) must be using a medically acceptable method of birth control and should not be pregnant nor have plans for pregnancy or breastfeeding during the study

Életkor a regiszterben: 40 év – 75 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Birmingham VA Medical Center, Birmingham, ALBirminghamEgyesült ÁllamokIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.